



CAPABILITIES BROCHURE

July, 2025

For Institutional Investors Use Only

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.

S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



DISCLOSURE STATEMENT

This presentation, including without limitation any information, estimates or projections contained herein or made in connection with this presentation, either in writing or orally or other format. (this "Presentation") is being furnished by or on behalf of S. Jordan Associates ("Company"). Any information contained in this Presentation is for informational purposes only and has not been independently verified. The Presentation may contain confidential and/or proprietary information and is provided for the exclusive use of the recipient and may not be reproduced, provided or disclosed to others, or used for any other purpose, without written authorization by S. Jordan Associates and the Company, and upon request must be returned to the Company or S. Jordan Associates.

S. Jordan Associates is not a Broker/Dealer, Financial Analyst, Financial Bank, Securities Broker or Financial Planner, and any recipient of this Presentation admoswledges and garees that S. Jordan Associates is not acting, nor is required to act, in any such capacity in connection with any transaction involving the Company pertaining to the matters contained herein. This Presentation is not intended to be and does not constitute financial advice or any other advice, is general in nature and not specific to any recipient. Recipients are responsible for their own investment research and investment decisions.

Recipients should not construe any such information or other material as legal, tax, investment, financial, or other advice. Nothing contained on this Presentation constitutes a solicitation, recommendation. endorsement, or offer by the Company or S. Jordan Associates or any of their affiliates or any third party service provider to buy or sell any securities or other financial instruments in this or in any other jurisdiction in which such solicitation or offer would be unlawful under the securities laws of such jurisdiction. This Presentation does not address the circumstances of any particular individual or entity. S. Jordan Associates is not a fiduciary by virtue of any person's use of or access to this Presentation or the information contained herein. Recipients alone assume the sole responsibility of evaluating the merits and risks associated with the use of any information or other content in this Presentation before making any decisions based on such information or other content.

The Company, S., Jardan and Associates and their respective affiliates make no representation or warranty (express or implied) as to the accuracy or completeness of this Presentation and none of them will have any liability for any recipient's use of this Presentation or any other gral, written, or other communications transmitted to the recipient in the course of its evaluation of the Company, including without limitation, any improper use or defamatory, offensive, or ilegal conduct of recipient or any other users. This Presentation is provided on an "as is" basis without warranties of any kind, either express or implied, including but not limited to warranties of title or implied warranties of merchantability or fitness for a particular purpose. The disclaimers of liability contained herein apply to any damages or injury caused by any failure of performance, error, omission, interruption, deletion, defect, delay in operation or transmission, computer virus, communication line failure, theft or destruction or unauthorized access to, alteration of, or use of record, whether for breach of contract, tortious behavior, nealigence, or under any other cause of action. In exchange for accessing this Presentation, recipients garge not to hold Company or S. Jordan Associates or any of their affiliates or any third-party service provider liable for any possible claim for damages arising from any use by or decision made by recipients based on information or other content made available to recipients in or through this Presentation.

Any recipient of this Presentation acknowledges and agrees that the Company, S. Jordan Associates and their affiliates are not liable for any use of this Presentation or reliance on any information from this Presentation. In no event will the Company, S. Jordan Associates or any of their affiliates be liable for any direct, incidental, special, or consequential damages (including but not limited to lost profitsor trading losses) arising out of the use of or inability to use this Presentation. S. Jordan Associates and their affiliates do not endorse and are not responsible for the accuracy or reliability of any opinion, advice, information or statement on this Presentation.

This Presentation includes certain forward-looking statements, estimates and projections provided by, and with respect to the articipated future performance of, the Company, In some cases, recipients can identify forward-looking statements by terminology such as "may", "estimates", "anticipates", "intends", "will", "should", "could", "expects", "befeves", or "predicts". Such statements, estimates, and projections reflect various assumptions and elements of subjective judgment made by management concerning anticipated results, which are subject to business, economic, and competitive uncertainties and contingencies, many of which are beyond the control of the Company and which may or may not prove to be carrect. This Presentation contains certain projected financial information that reflects management's projections as to anticipated future results based upon assumptions that are inherently uncertain, including assumptions as to the size of the market in which it competes, general industry conditions, and other factors. The assumptions are based upon management's judgment. As a result, no representation or warranty is made as to the feasibility of the projected financial information included in this Presentation. This Presentation is not, and under no arcumstances should be construed as, a salicitation to act as a securities broker or dealer in any jurisdiction. Recipients should not regard this Presentation as a substitute for the exercise of their own judgment. The Company reserves the right to negotiate with one or more prospective third parties at any time and to enter into a definitive agreement relating to a transaction with the Company without grior notice to the recipient or other prospective third parties. Also, the Company reserves the right, at any time, to terminate the further participation in the investigation and process by any party and to modify any procedures without giving advance notice or providing any reason thereof. The Company also reserves the right during the evaluation period to take any action, whether within or outside the ordinary course of business, Neither this Presentation nor its delivery to recipients shall constitute or be construed to be an offer to sell any securities of the Company, Neither the Company nor S. Jardan Associates expects to update or otherwise revise this Presentation or other materials supplied herewith.



OPERATIONAL, BUSINESS DEVELOPMENT, AND BANKING EXPERIENCE



FOUNDER / CEO
Broker Dealer – Finalis Securities
https://www.linkedin.com/in/sjordan1/

SCOTT JORDAN - Series 7

COREY MENDOZA

- C-Level Operations Experience Chief Financial Officer (CFO) / Chief Business Officer (CBO) for private and public (NASDAQ) biotechnology companies leveraging non-dilutive funding, strategic partnerships, and the capital markets to advance client development programs through proof-of-concept clinical studies
- Business Development / Investment Banking Expertise Over 30 years of structuring licensing agreements, closing Seed / Series rounds, cross-over financings, equity lines, and \$1 / \$3 shelf offerings
- Facilitated "Exits" via Mergers and Acquisition (M&A), Initial Public Offerings (IPOs), and Alternative Public Offerings (APOs - Special Purpose Acquisition Companies - SPAC / reverse mergers)



CHIEF MARKETING OFFICER
https://www.linkedin.com/in/corevimendoza/

An award-winning Executive Producer, Writer, Director, Editor, Designer, Musician, and Marketing Strategist with over 25 years of professional experience. His expertise is in brand development, marketing & advertising, video and television production, and creative design.

AWARDS:

- (5) Emmy Awards for "Minds of Medicine & "Vital Signs" (NATAS/Mid-Atlantic)
- (3) Telly Awards for "Best Production" in Television "Gold Coast Reality"
- (5) Axiem Awards for "Absolute eXcellence" in Digital Media
- (3) Silver Mic Awards for Advertising Commercials
- (2) MarCom Creative for regional Advertising Campaign



INVESTMENT BANKER

Broker Dealer – Finalis Securities /
Collabrity

https://www.linkedin.com/in/chislehman/

CHRIS LEHMAN - Series 79

- Seasoned financial and business development executive in the life sciences industry with an exceptional
 combination of strategic partnering & financial leadership experience; 25+ years with venture-backed
 private and public industry leaders in therapeutics, diagnostics, CRO and industrial biotech
- Led or supported 28+ partnering and financing transactions totaling \$950 million
- Direct experience in leveraging broad industry network with investment banks, venture capital, equity research analysts and strategic pharmaceutical partners to raise dilutive and non-dilutive capital; conducted numerous presentations to potential investors and partners in the United States, Europe and Asia. Founded and grew a successful strategy advisory firm with 20+ client engagements



S. JORDAN ASSOCIATES (SJA) SERVICE OFFERINGS

NON-DILUTIVE FUNDING

S. Jordan Associates (SJA) is proficient identifying non-dilutive capital sources from Local, State (Cancer Prevention Research Institute of Texas - CPRIT) and Federally sponsored institutions (NIH / SBIR)

Guide clients through the application process and work collaboratively to implement best practices leading to successful awards





STRATEGIC ADVISORY / BUSINESS DEVELOPMENT

SJA engages with strategic partners seeking to outsource R&D via traditional and novel partnerships (option-to-buy / licensing, co-development). Services provided to emerging growth companies include:

- Assessing the competitive landscape and benchmarking against industry deal averages (upfront payments, royalties, milestones)
- Targeted outreach to large biopharmaceutical, diagnostic, and medical device companies managed within SJA's proprietary Customer Relationship Management (CRM) system
- Negotiating term sheets with prospective partners optimizing client deal metrics and shareholder return on investment (ROI)

PRIVATE COMPANY FINANCINGS

SJA exceeds client financing objectives by accessing the company's extensive network of institutional, angel groups, and alternative investors (accredited, family offices, hedge funds) to finance early to mid-stage biotech companies through major value inflection points / milestones

Effective at negotiating and closing Seed / Series rounds with institutional capital sources (venture capital, cross-over) and identifying / securing commitments from "Lead" sponsors pivotal to securing investor syndicates

"EXITS" / PUBLIC COMPANY FINANCINGS

SJA works diligently evaluating viable exit / public company financing vehicles including mergers and acquisitions (M&A), initial public offerings (IPOs), and alternative public offerings (reverse merger, SPAC) aligned with capital market conditions and company-specific attributes

Alternative Public Offerings (APOs):

Leverage strong relationships with sell-side banks and reverse merger / SPAC sponsors identifying public shells, submitting proposals to win auctions, and negotiating / closing term sheets on behalf of private companies seeking to list on public market exchanges (e.g. NASDAQ)



ACHIEVEMENT 2024: RADIOPHARMACEUTICALS

Telix Completes Acquisition of Next-Generation Therapeutic Assets and Innovative Biologics **Technology Platform**





ASSET SALES – IMAGINAB / TELIX PHARMACEUTICALS

- Telix announced asset acquisition from antibody engineering company ImaginAb, Inc. The acquisition includes a pipeline of next-generation therapeutic candidates, a proprietary novel biologics technology platform, and a protein engineering and discovery research acility to enhance existing innovation capabilities.
- Iransaction delivers a pipeline of drug candidates against validated cancer targets including DLL3 and integrin avB6, as well as a panel of other agents against novel targets in early discovery stage.
- The technology platform and intellectual property utilizes small, engineered antibody formats that enable highly specific tageting of cancer with radiation, that exhibit fast tumor uptake and clearance from the blood.
- This technology has the potential to be highly effective for imaging and treating tumors with a broad range of radioisotopes, with alpha emitters of particular interest.
- The ImaginAb capabilities combined with Telix's existing investments in new target development, conjugation and isotope processing has resulted in a platform that has the potential to rapidly create a new portfolio of "next generation" theranostic radiopharmaceuticals.

Jefferies

Syndicate Banker



ACHIEVEMENTS 2021-2023: GENE THERAPY & IMMUNE-ONCOLOGY

NON-DILUTIVE FINANCING – INOMAGEN THERAPEUTICS

- S. Jordan Associates (SJA) acted as financial advisor to Inomagen
 Therapeutics assisting with securing a \$3.67M NIH SBIR Fast Track Phase 1/2
 Grant to develop a novel gene therapy for Atrial Fibrillation (AF)
- The award includes \$462,689 from the National Heart, Lung, and Blood Institute (NHLBI) to complete the 'Phase 1' segment of development which includes optimizing gene doses and electroporation parameters required for atrial gene delivery
- Upon successful completion of the Phase 1 segment, Inomagen eligible to receive an additional \$3,212,600 in NIH funding to carry out the 'Phase 2' segment, which will include determining optimal dose of gene therapy required to attenuate established electrical remodeling in AF

ABOUT INOMAGEN THERAPEUTICS, www.inomagen.com

 Inomagen Therapeutics, Inc. is a privately held biotechnology company with technology licensed from Northwestern University (NU) dedicated to delivering the promise of gene therapy for treating serious cardiovascular diseases such as atrial fibrillation



\$3.67M NIH SBIR



Non-Dilutive Funding



PRIVATE COMPANY FINANCING - IMMUNOGENESIS

- S. Jordan Associates (SJA) acted as financial advisor to ImmunoGenesis assisting with raising a \$14.5M convertible note
- Lead investors include the founders of Chicago-based hedge funds (Magnetar Capital and Peak6), early-stage venture capitalists (BioAdvance, Texas Halo Fund) and secondary markets trading firm / cross-over investor (Adit Ventures)

ABOUT IMMUNOGENESIS, www.immunogenesis.com

- ImmunoGenesis formed to develop products from the lab of Dr. Michael A. Curran, Associate Professor, Department of Immunology at MD Anderson Cancer Center who worked closely with Nobel Laureate, Dr. James Allison, and is on the patent for CTLA-4 (cytotoxic T-lymphocyte-associated protein 4 Ipilimumab / Yervoy) inhibition
- Development programs to overcome immune resistance in "cold" tumors unresponsive to current checkpoint inhibition therapies which comprise the majority of all cancers



\$14.5M Convertible Note



Private Placement



ACHIEVEMENTS: 2016 - 2020

NON-DILUTIVE FUNDING

- Secured awards from the Cancer Prevention Research Institute of Texas (CPRIT) resulting in ~\$35M of non-dilutive capital advancing three drug programs through Investigational New Drug (IND) enabling studies
- Leveraged non-dilutive capital during early stages of development to reach critical milestones resulted In subsequent financing rounds priced at higher valuations



STRATEGIC ADVISORY/ BUSINESS DEVELOPMENT

- Out-licensed South Korean rights to Salarius Pharmaceuticals / Iterion Therapeutics' lead compounds (Seclidemstat, Tegavivint) to HLB Lifesciences Co.
- Negotiated licensing terms including upfront payment, milestones, and royalties
- Established joint research committees monitoring progress and report findings to respective board members





PRIVATE COMPANY FINANCINGS

Raised development funding from a cademic Institutions, angel groups, and accredited / institutional investors (venture capital)



"EXITS" / PUBLIC COMPANY FINANCINGS

- Identified, awarded, negotiated, and closed a term sheet / public shell with Flex Pharma (FLRX) resulting in Salarius Pharmaceuticals listing on NASDAQ via a reverse merger in 2019
- Facilitated a \$10.9M equity line with Aspire Capital, a private, long-only investment fund focused on making investments in publicly traded companies
- Closed a \$11M S1 offering with Ladenburg Thalmann funding Salarius through Phase 1 / 2 clinical milestones





TOMBSTONES: 2016 - 2020





S1 OFFERING





\$6.4M Convertible Preferred



REVERSE MERGER



FLEXPharma

\$46.3M Deal Value

SERIES SEED



EQUITY LINE



KspireCapital

S. KOREAN RIGHTS





TRANSACTION HISTORY: 2005 - 2016









AI / MACHINE LEARNING – IQ500

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.

S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



SJA PARTNERED WITH IQ500 – LEADER IN AI / MACHINE LEARNING



1Q500 connects Issuers. Investors, and Strategic Acquirers directly via an intelligent infrastructure that modernizes the entire private investment continuum from investment research and market analysis to relationship mapping, networking, opportunity screening, communication, transaction management, due diligence, FAQs, valuation, syndication, deal execution, benchmarking, performance measurement, and exit planning.

Powered by machine learning which accurately predicts investments with 93% statistical precision, IQ500 seeks to transform the efficiency of the \$480 billion Venture Capital market by streamlining investment selection, risk management, and outcome realization.

Machine Learning Algorithm: Trained on 2 million VC transactions using 160 million analytical arrays across 800-dimensional vectors








1Q500 - RIGHT PERSON, RIGHT DEAL, RIGHT TIME



WHICH INVESTORS ARE BEST FOR THE COMPANY?

Financial and strategic targets which are 93% likely to lead the Company's next transaction.





WHO DO WE CONTACT? WHY? HOW?



Individual target contact affiliations. Direct, encrypted, "1:1" communication through MS Teams



WILL THERE BE INTEREST IN OUR DEAL?



Real-time, "in aggregate" data of activity by financial and strategic targets on Company listing



WHEN WILL THE DEAL CLOSE?





KPI's, including strength of relationships; deal quality; likelihood of success; timing of close.



IQ500 – BENEFITS FOR ISSUERS



Each Company listing on **IQ500** features a range of deal experiences — solving the most important problems — and intended to support financial and strategic success throughout the business horizon.

HOW DO WE COMPARE?

Peer Groups which place each Company among its closest "competitors", as established by investors and strategic participants on Company's target lists.



										b-
An Evipore	_=	-	-	ä	-	sametha s	Ή	-	1	-
time Western Co.	100	44	-	-	- 0.0	Service 2010	-	- 11	-	_
Making Makar Indicates	100	Deb	West -	(18)	10.7	Name of State	701	8.6	903	99.1
Steering Terror Stellar Statement Co. 100.	110	.019	Dine		2.0	Fitness E 2001	218	44	desi	. 4
Appropriate for	146	94	painting.		- 1	HARRY P. PRIN	0.4	93	901	200
Contract DWS	4.00	479	Synn		. 40	Thereton 1, 801	104	17	- 04	44
Congress Science (ACC)	146	34	Band.	10.7		W404 5 765	363	- 14.	104	(44.7)
StreCommission in	0.00	mot.	(marine		190.0	Opening 1: 450	61.0	- 10	911	41
more in	4,011	-0.0	Distribution.		80	Departure h. Prill	163	24	201	4
Consult Reduction	100	011	0.0		41	Storde 8, 705	76.6		- 80	90
Figure 4 Notifi	144	-0.0	- Date:	- 2	90	March 2 474	41	- 14	0.00	180
CONTRACTOR CORP. CT. CT.	100	41	less.		163	160-5-300	No. o	- 04	300	. 0.
Permitted in	144	360	Denti :	1.0	46	200,000	44	19	10 DW	44.
Day of Santanage 115	2101	91	040		0.1	About 10 (MI)	-0.1	0.6	0.0	81 .
months he	446	44	phone.	- 5	. 40	decores 3-200	36.6	- 47	- 64	- 6
ADDRESS NO.	134	273	PERM		8.0	Reservoir's Jest	160	14	80	
Total New York Street	-3.60	-44	(real-law)	0.00	94.7	-04-6-00	44.6	1.0	10.746	X 80.00
Decree Sprantheon Sprants and	4 84	20.00	lime		90	Desired St. 2010	91	- 0.0	- 01	
New Arthresis Inc.	:04	200	(resident	(0.97)	965	Sector 20, 2007	70.0	19	100	784
Marie Triangular, No.	110	41	-		81	Assista tier	74	- 41	194	-
Manager Service Chief	100	200	Total 1	-	9.9	Distance for person	10.0		- 04	Dari.

WHAT IS OUR VALUATION? EXIT PATH?

| Section | Sect

Precedent Transactions, Public Comparables




WHAT IS HAPPENING IN OUR MARKET? WITH INVESTORS, BUYERS, PEERS?

Customized market data, competitive analysis, news, social sentiment.






OPTIMIZE INVESTOR TARGET LISTS / ENGAGEMENT / CLOSING







EMAIL MARKETING: NURTURING RELATIONSHIPS THROUGH EMAIL CHANNEL





EMAIL MARKETING STRATEGY: OPTIMAL MESSAGE, AUDIENCE, TIME







MESSAGING CONTENT

- General Outreach / Brand Recognition
- News Update
- Event Sign Up
- Collaboration
- Capital Raising / Partnering

TARGETED AUDIENCE

- Strategic Partners
- Key Opinion Leaders
- Bankers

TIMING

- Highest Open Rate
- Highest Engagement Rate
- Campaign Specific Time Sensitivity





UTILIZING HUBSPOT DATA TOOLS (CRM) TO MEASURE SUCCESS



DELIVERY RATE Delivered

- •Bounced

OPEN RATE

- •Desktop Vs. Mobile
- Email Providers

EMAIL VIEW TIME

- Read
- Glanced

HTML CLICK MAP

- Location Of The Clicks On The
- Optimization(s) For Button, Links, Graphics

CLICKED LINK(S)

· Content Clicked

LEAD SCORING

 Content engagement score for prioritization

AUTO-ADVANCE LIFE CYCLE STAGES

- Leads
- Scheduled a call
- Won / lost

DASHBOARD

- Performance review
- Team discussion



DATA IS POWER

FOLLOW UP COMMUNICATIONS

NEWS

GROUP **ENGAGEMENT**

Automated "workflow" (marketing) email to those that opened but did not engage

"Workflow" email targeting specific email group (i.e. more science)

PERSONAL **ENGAGEMENT**

CRM

Automated "sequence" (personal) email to those based on their engagement



One-on-one messaging based on personal interaction

Ensure conversations and activities connected to the contact database for continuous learning and optimization?























APO SERVICES: INCEPTION TO CLOSING

APO COORDINATION

S. Jordan Associates manages APO Process on Behalf of Reverse Merger Sponsors (Banks) / Private Companies Including the facilitation of Public Company Readiness and Capital Supporting Transactions



LEGAL / PUBLIC COMPANY READINESS



PROJECT MANAGEMENT / **CAPITAL SUPPORT**



Close

LEGAL

- Legal advice and document preparation / negotiation including M&A, tax and securities law
- SEC disclosure and periodic reporting guidance

STEPHEN ALICANTI

FINANCE / INTERIM C-LEVEL

- Evaluation and implementation of financial controls
- Recruiting and leading the internal accounting and finance team members
- Investor and public relations strategies and leadership

STEVE JOSEPH



ACCOUNTING / CONTROLS

- Audit readiness
- S-4 prep (F Pages, MDA, Pro Forma)
- Internal controls
- · Accurate, reliable and timely KPI and financial reporting

MIKE MONTGOMERY



INVESTMENT BANKING

- Forecasting and financial / cash flow modeling
- Capital raises including venture capital (Series A>), concurrent and cross-over financings (PIPES), and public market offerings (\$1, S3)
- Introduction to reverse merger sponsors
- Term sheet negotiations

Scott Jordan



Affiliated Partners



APO WEBINAR

STRONG TRACK RECORD OF FACILITATING APO'S IN THE LIFE SCIENCES INDUSTRY

APO Webinar, "Reverse Mergers and SPACS:

"Are Alternative Public Offerings the New Normal For Biotech's Going Public?" – March 18th, 2021 https://hubs.ly/H0JLhtK0



SCOTT JANSSEN Managing Director LS Associates

partnering / BD , and virtual



MIKE MONTGOMERY Managing Partner Effectus Group



SCOTT JORDAN Founder / CEO S Jordan Associates

APOs – Reverse / SPAC



APO PUBLIC READINESS CHECKLIST

Strategic

Have you built an IPO or Reverse Merger roadmap with specific subject matter experts, work stream, and milestones?

Who is the project owner / manager and do they have experience with this complex process?

Has the board reviewed the plan and key dates?

Have you performed a Board "audit" to make sure you have the people, skills, and governance in place to lead a company into and operate effectively as a public company?

Are the internal shareholders and experts on the Board held accountable for their portion of the project?

Have you engaged a team of expert consultants to support the project (e.g. attorney's, financial and technical accounting, consultants,

auditors, D&O insurance providers)?

Have you prepared accurate, reliable, and timely financial and scientific reports that will be required as a public company?

Do you have reliable forecasting and subsequent actual to forecast reporting?

Finance / Accounting

Reviewed monthly closing book process / gap analysis necessary?

Team in place to implement financial planning and analysis including the review of budgt vs. actual processes?

Audited financials? If not, has the company received auditations from potential auditing firms?

Company discussed with management / Board final selection of auditors?

Company worked with auditors / director of finance from an accounting firm to complete the audit?

Completed a 409A valuation that can be substantiated under PCAOB standards?

Reviewed the cap table ensuring all supporting documentation in place including all financial transactions?

Set up data base to collect company information such as contracts, stock option grants, financial statements for efficient audit process?

Capital Raise

Developed a plan and timeline for next financing?

Completed an investor deck review by Investor Relations and financial experts ensuring syneraistic with financial forecasts and budget?

Reviewed 5 / 10-year financial plan and balance sheet?

Reviewed a list of possible Series / Cross-over investors and selected a banker to assist with the process?

Initiated the IPO / Reverse Merger roadmap with estimated timelines, assigned workstreams to stakeholders and consultants?





APPENDIX #1 – SJA PRIVATE PLACEMENT SERVICES AND TIMELINES

Securities are offered through Finalis Securities LLC Member FINRA/SIPC.

S. Jordan Associates and Finalis Securities LLC are separate, unaffiliated entities.



SJA SERVICE OFFERINGS

LEVEL	MONTHLY ENGAGEMENT FEE (\$)	SJA SUCCESS FEE (%)	COMPANY PROFILE: FUNDING ROUND / STAGE OF DEVELOPMENT; SERVICES PROVIDED	SERVICE OFFERINGS	DESCRIPTION / AFFILIATED PARTNERS
1	\$1,250	No	 Funding Round: Seed – Series Rounds Stage of Development: Pre / Clinical Services: Private Placements, M&A (Client Directed) 	> IQ500	Client Subscription
2	\$4,000 - \$6,000	Yes	 Funding Round: Seed – Series Rounds Stage of Development: Pre / Clinical Services: Private Placements, Business Development / Licensing 	> SJA > IQ500 > Finalis	IQ500 – Client Subscription with SJA In Supervisory Role Syndicate Investors Through Finalis Broker Dealer Network
3	\$8,000 – 10,000	Yes	 Funding Round: Series A / B Stage of Development: Pre / Clinical Services: Valuations, Fairness Opinions, Private Placements, M&A, Business Development / Licensing, Non-Dilutive Capital 	> SJA > IQ500	Full Banking Engagement Leveraging Al
4	\$15,000	Yes	 Services: Private Companies: Alternative Public Offerings (APOs), PIPES, Pre-IPO Prep Public Companies: Reverse Splits / Stock Exchange Compliance 	> SJA > IQ500 > Collabrity	Channel Partner, Collabrity, Available to Assist with Pre-IPO Readiness / Crossover Financings



PRIVATE PLACEMENT TIMELINE

MONTH 1

PREPARATION

MONTHS 2-4

TARGETING / ENGAGEMENT

MONTHS 5-6

EXECUTION / CLOSE

Review / Prepare Marketing Documents

- Executive Summary / Teaser
- Non-Confidential Deck
- Confidential Deck
- Supporting Documents

Valuation Model

- Discounted Cash Flow (DCF)
- 'Comp' Analysis

Finance

- Financial Statements
- Cap Table

Securities / Legal

- SEC Filings: 506b / 506c
- Term Sheet
- PPM (Optional)

Data Room

- Frame the Architecture
- Load Documents / Content
- Set Permissions

Target Investors Matching Company Profile (Therapeutics Example)

- Investor Types: Institutional, Alternative (Accredited, Family Office)
- Funds Actively Investing
- Modality: Small Molecules, Biologics, Gene / Cell Therapy
- Development Stage: Pre / Clinical / NDA / Approved
- Financing Stage: Early (Seed / Series A) to Later-Stage (Series B>)
- Financing Amount (\$M)

Marketing / Outreach

- Referrals
- Email
- Social Media / Linkedin
- Conferences
- IQ500 / AI

Engagement Analytics / Reporting

- Opens / Clicks / Viewed Deck / Landing Page
- Scheduled Calls
- Weekly 1:1 Meetings / Investor Tracker

Diligence / Confidential Review

- CDAs Sent / Executed
- Data Room Access
- Confidential Management Presentations

Negotiation of Terms

NPV Analysis

Sign Agreement

Receipt of Funding

- Cash
- Stock
- Other: Contingent Value Rights (CVR)

Add Investor(s) to Cap Table

Public Announcement



FINALIS SECURITIES / SYNDICATION




Syndicate Capital Raises / M&A within Finalis' Broker Dealer Network

The Finalis Network Footprint



Number of Active Deals by Transaction Type

1,931 Active Transactions within the Finalis Network








SALARIUS PHARMACEUTICALS REVERSE MERGES INTO FLEX PHARMA

- Salarius Pharmaceutical (Nasdaq: SLRX), a clinical-stage oncology company targeting the epigenetic causes of cancers, announced closing a merger with Flex Pharma, Inc.'s wholly owned subsidiary on July 19, 2019
- The newly combined company focused on the continued development of Salarius' clinical pipeline, which targets rare, orphan cancers with lead compound, Seclidemstat, a LSD1 inhibitor (epigenetics validated target)
- Healthios Capital Markets (now Third500 https://www.third500.com/) served as financial advisor in the transaction to Salarius Pharmaceuticals and Wedbush PacGrow advised Flex Pharma

Allocation Percentage - from Summary of Proposed Terms	\$M	%	
Flex Enterprise Value - "Shell"	\$7.2		
Flex Cash at Close	\$3.1		- FLEXPharma
Flex Total Fair Value	\$10.3		
Salarius Total Fair Value	\$36.0	→	Salarius PHARMACEUTICALS
Total Fair Value of Newco	\$46.3	→	\$46.3M DEAL VALUE
Allocation Percentage			
Flex		22.3%	
Salarius		77.7%	



TIMELINE / MILESTONES FROM INCEPTION TO REVERSE MERGER CLOSING







SERVICE OFFERINGS

SERVICE	DESCRIPTION	PRICE		
IQ500 Monthly Subscription	Access to IQ500 – Profile, Top 100 Investors, Strategic Partners, Data Room	\$1,250 / Mo.	Cancellable Monthly	
Document Review	Executive Summary, Management \$5,000		Optional	
Document Development	Executive Summary, Management Presentation	\$15,000	Optional	
Financial Model Development	Progressive To "Peak" Value	\$20,000	Optional	
EcoSystem Review	Network, Relationships, Targets, Peers, Exit Comps, M&A Precedents	\$2,500	Optional	
Network Development	Warm Introductions, Referrals, Notifications	\$2,500 / Mo.	Optional	
Deal Monitoring	Performance Tracking, Benchmarking, Data Analysis, Reporting	\$1,000 / Mo.	Optional	
Deal Management	Network Development, Deal Monitoring, Plus Target Engagement	\$5,000 / Mo.	Optional	
Total Listing Management	All The Above	\$7,500 / Mo.	Optional	
Deal Syndication	For Issuers And VC's	% Spread	Optional	
Secondary Transactions	For Issuers And VC's	% Spread	Optional	

